Azaquinazoline Inhibitors Of Atypical Protein Kinase C
申请人:Ignyta, Inc.
公开号:US20150274720A1
公开(公告)日:2015-10-01
The present application provides a compound of formula (I)
and/or a salt thereof, wherein R
1
, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME
申请人:Hopper Allen
公开号:US20110092475A1
公开(公告)日:2011-04-21
The present invention provides 2-substituted-ethynylthiazole derivatives of formula (I):
wherein R
1
, R
2
and X are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods of using same.
Novel compounds which are useful for treating acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumour pain and headache diseases. The following is exemplary:
The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.
Gegenstand der vorliegenden Erfindung Verbindungen der allgemeinen Formel I
in der A, B, D, Y, R1, R2, R3, R4 und R5 wie in Anspruch 1 definiert sind, deren Enantiomere, deren Diastereomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit organischen oder anorganischen Säuren oder Basen, welche wertvolle Eigenschaften aufweisen, deren Herstellung, die die pharmakologisch wirksamen Verbindungen enthaltenden Arzneimittel, deren Herstellung und deren Verwendung.